Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer.
+ 1 more risk
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Izotropic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IZO's share price has been volatile over the past 3 months.
7 Day Return
CA Medical Equipment
1 Year Return
CA Medical Equipment
Return vs Industry: IZO underperformed the Canadian Medical Equipment industry which returned 5.5% over the past year.
Return vs Market: IZO underperformed the Canadian Market which returned 4.5% over the past year.
Price Volatility Vs. Market
How volatile is Izotropic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Kind Of Shareholder Owns Most Izotropic Corporation (CSE:IZO) Stock?
3 months ago | Simply Wall StWill Izotropic (CNSX:IZO) Spend Its Cash Wisely?
7 months ago | Simply Wall StDoes Izotropic's (CNSX:IZO) Share Price Gain of 30% Match Its Business Performance?
Is Izotropic undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IZO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IZO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IZO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: IZO is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IZO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IZO is overvalued based on its PB Ratio (41.5x) compared to the CA Medical Equipment industry average (4x).
How is Izotropic forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Izotropic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Izotropic's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Izotropic competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Izotropic performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: IZO is currently unprofitable.
Growing Profit Margin: IZO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IZO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IZO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IZO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.4%).
Return on Equity
High ROE: IZO has a negative Return on Equity (-376.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Izotropic's financial position?
Financial Position Analysis
Short Term Liabilities: IZO's short term assets (CA$142.9K) exceed its short term liabilities (CA$10.1K).
Long Term Liabilities: IZO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IZO is debt free.
Reducing Debt: IZO had no debt 5 years ago.
Inventory Level: IZO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if IZO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IZO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IZO has less than a year of cash runway if free cash flow continues to reduce at historical rates of -22% each year
What is Izotropic's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IZO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IZO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IZO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IZO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Bob Thast (65yo)
Mr. Robert Louis Thast, also known as Bob, has been the President and Chief Executive Officer of Maxore Minerals Corp. since March 15, 2007. He has been the President of Thast Projects Inc. since April 199 ...
|CEO, President||3.8yrs||no data||21.25% CA$1.5m|
|VP of Marketing & Director||2.8yrs||no data||1.67% CA$120.0k|
|Medical Device Business Consultant & Member of Advisory Board||0yrs||no data||no data|
|Director||0yrs||no data||no data|
|Senior Advisor & Member of Advisory Board||0yrs||no data||no data|
|Senior Development & Technology Advisor and Member of Advisory Board||0yrs||no data||no data|
|Independent Director||2.8yrs||no data||3.34% CA$240.0k|
|Member of Advisory Board||0yrs||no data||no data|
|Independent Director||2.8yrs||no data||1% CA$72.0k|
|Member of Advisory Board||0yrs||no data||no data|
Experienced Board: IZO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Izotropic Corporation's company bio, employee growth, exchange listings and data sources
- Name: Izotropic Corporation
- Ticker: IZO
- Exchange: CNSX
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$7.192m
- Shares outstanding: 29.97m
- Website: https://izocorp.com
- Izotropic Corporation
- 800 – 15355 24th Avenue
- Suite 424
- British Columbia
- V4A 2H9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IZO||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Jun 2018|
|IZOZ.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jun 2018|
|1R3||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2018|
Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3-D breast CT imaging technology for early diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 01:08|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.